Showing results (1-10 of 1,085) with videos related to
Sort By:
Pageof 109
Circulation|June 16, 2004
Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk?Paul M Ridker, Peter W F Wilson, Scott M GrundyClinical Cardiology|April 24, 2003
Connecting the role of C-reactive protein and statins in cardiovascular diseasePaul M RidkerCurrent Atherosclerosis Reports|December 11, 2012
Moving beyond JUPITER: will inhibiting inflammation reduce vascular event rates?Paul M RidkerCirculation Research|February 1, 2019
Anticytokine Agents: Targeting Interleukin Signaling Pathways for the Treatment of AtherothrombosisPaul M RidkerCirculation Research|February 4, 2016
From C-Reactive Protein to Interleukin-6 to Interleukin-1: Moving Upstream To Identify Novel Targets for AtheroprotectionPaul M RidkerAmerican Heart Journal|June 24, 2004
High-sensitivity C-reactive protein, inflammation, and cardiovascular risk: from concept to clinical practice to clinical benefitPaul M RidkerTransactions of the American Clinical and Climatological Association|July 23, 2013
Closing the loop on inflammation and atherothrombosis: why perform the CIRT and CANTOS trials?Paul M RidkerJournal of the American College of Cardiology|November 13, 2018
Clinician's Guide to Reducing Inflammation to Reduce Atherothrombotic Risk: JACC Review Topic of the WeekPaul M RidkerCurrent Atherosclerosis Reports|June 9, 2009
Moving toward new statin guidelines in a post-JUPITER world: principles to considerPaul M RidkerVascular Pharmacology|October 23, 2023
Targeting residual inflammatory risk: The next frontier for atherosclerosis treatment and preventionPaul M RidkerPageof 109